HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo therapy for advanced cancers shows early safety data
Disease control TerminatedThis early-phase study tested a new drug called TNO155 combined with either spartalizumab or ribociclib in 122 adults with advanced solid tumors (lung, head and neck, esophageal, stomach, and colorectal cancers). The main goal was to check safety and find the right dose. The stud…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 22:49 UTC
-
New drug combo tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to see if the treatment was safe and to look for early signs of tumor shrinkag…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Head and neck cancer drug combo trial ends early
Disease control TerminatedThis study tested a new drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The trial was stopped early by the sponsor, so r…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Cancer combo trial halted: immunotherapy plus radiation for head and neck cancer
Disease control TerminatedThis study tested whether adding radiation therapy to the immunotherapy drug pembrolizumab could help people with advanced head and neck cancer that had spread. The trial was for patients whose cancer had gotten worse after initial treatment. The study was stopped early, so resul…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors like sarcoma, kidney cancer, and melanoma. The goal was to find a safe dose and check for side effects. The study was terminated, so results are limited.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Experimental drug targets Hard-to-Treat cancers, but trial ends early
Disease control TerminatedThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
New cancer drug combo tested in early trial
Disease control TerminatedThis early-phase study tested a new drug, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
Tiny trial tests smarter chemo delivery in head and neck cancer
Knowledge-focused TerminatedThis very early study looked at how a new version of the chemotherapy drug paclitaxel (called FID-007) affects immune cells around head and neck tumors. The drug is wrapped in a special polymer to help it reach deeper into tumors while sparing healthy cells. Only 1 person enrolle…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:05 UTC